Literature DB >> 1834308

Cerebrovascular and functional consequences of 5-HT1A receptor activation.

D E McBean1, J Sharkey, I M Ritchie, P A Kelly.   

Abstract

Cerebral glucose utilization and blood flow were measured in rats using 2-deoxy-D-[14C]glucose and [14C]iodoantipyrine quantitative autoradiography, respectively, following treatment with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). In control and 8-OH-DPAT-treated animals blood flow and glucose use were similarly correlated, but the ratio was increased following 8-OH-DPAT treatment. Since 5-HT1A receptor activation is known to reduce neuronal 5-HT release, these results are consistent with a vasoconstrictor role for endogenous serotonin.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1834308     DOI： 10.1016/0006-8993(91)90873-t

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  4 in total

1.  Effect of the 5-HT1A partial agonist buspirone on regional cerebral blood flow in man.

Authors:  P M Grasby; K J Friston; C Bench; P J Cowen; C D Frith; P F Liddle; R S Frackowiak; R J Dolan
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  MDMA 'ecstasy' increases cerebral cortical perfusion determined by bolus-tracking arterial spin labelling (btASL) MRI.

Authors:  J Rouine; O L Gobbo; M Campbell; V Gigliucci; I Ogden; K McHugh Smith; P Duffy; B Behan; D Byrne; M E Kelly; C W Blau; C M Kerskens; A Harkin
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

3.  Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilisation in the Dark Agouti rat.

Authors:  Linda Quate; Douglas E McBean; Isobel M Ritchie; Henry J Olverman; Paul A T Kelly
Journal:  Psychopharmacology (Berl)       Date:  2004-02-20       Impact factor: 4.530

4.  Brain aging research at the close of the 20th century: from bench to bedside.

Authors:  C Cidis Meltzer; P T Francis
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.